ASLAN Pharmaceuticals

You are now leaving our web site.

The Website may contain links to or from other websites, over which ASLAN has no control. These linked sites are for your convenience only and you access them at your own risk.

ASLAN is not responsible for the content of the linked sites. ASLAN does not in any way endorse the linked sites.

I understand

News & Publications

Read about our latest product developments and partnerships, industry advances and events.

News

ASLAN Pharmaceuticals to present positive varlitinib data in first-line biliary tract cancer in combination with chemotherapy at ASCO GI

ASLAN Pharmaceuticals today announced positive data from an ongoing multicentre phase 1b/2 clinical trial (ASLAN001-007) of varlitinib plus gemcitabine and cisplatin (gem/cis) in first-line biliary tract cancer (BTC). Varlitinib in combination with gem/cis has been well tolerated in BTC patients and the data also demonstrate increased activity of varlitinib in combination with gem/cis compared to gem/cis alone.

The data will be presented during a poster presentation at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco on 18 January 2019.

For more information, please refer to the English or Chinese press release.